Adjuvant endocrine therapy for post-menopausal women with ductal carcinoma in situ—is the pain worth the gain?—a commentary on the NSABP-B35 trial

The recent publication of the NSABP-B35 trial provides important information about the relative value of anastrozole (ANA) over tamoxifen (TAM) for post-menopausal women with ductal carcinoma in situ (DCIS) treated with conservative surgery (CS) and radiotherapy (RT). However, the clinician is still left wondering when adjuvant hormonal treatment (HT) should be prescribed for the individual patient and now whether to use ANA instead of TAM (1).